<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04805073</url>
  </required_header>
  <id_info>
    <org_study_id>IRB202002297-A</org_study_id>
    <secondary_id>OCR40099</secondary_id>
    <nct_id>NCT04805073</nct_id>
  </id_info>
  <brief_title>Treatment of Pruritus With Intramuscular Promethazine</brief_title>
  <official_title>Assessing Efficacy of Intramuscular Promethazine for the Treatment of Intrathecal Morphine Induced Pruritus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neuraxial narcotics are commonly used in obstetric patients for cesarean delivery to help&#xD;
      with pain control over the first 24 hours after the surgery. The aim is to evaluate&#xD;
      effectiveness of promethazine (IMP) treatment of intrathecal morphine induced pruritus&#xD;
      (ITIMIP). A treatment for ITMIP, other than naloxone, will allow for increased use of&#xD;
      intrathecal narcotics and decrease the use of systemic opioids in the initial post-operative&#xD;
      period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 9, 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Stratified randomization design</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Prophylactic intramuscular promethazine does change pruritus in post-partum females that received 100mcg intrathecal morphine</measure>
    <time_frame>Within first 24 hours post cesarean section</time_frame>
    <description>Pruritus will be quantified by the ItchyQuant Scale with 0 -10 scale with 0=no itch and 10-the worst itch</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Promethazine does not change sedation compared to placebo</measure>
    <time_frame>Within first 24 hours post cesarean section</time_frame>
    <description>As quantified by the RASS scale with +4 to -5 scale with +4=combative and -5=unrousable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Promethazine does not change pain compared to placebo</measure>
    <time_frame>Within first 24 hours post cesarean section</time_frame>
    <description>As quantified by the DVPRS scale with 0-10 scale with 0=no pain and 10=as bad as it could be, nothing else matters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Promethazine change in nausea and vomiting</measure>
    <time_frame>Within first 24 hours post cesarean section</time_frame>
    <description>rated as none, mild, moderate, severe</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Pruritus</condition>
  <condition>Pregnancy Related</condition>
  <arm_group>
    <arm_group_label>Promethazine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The treatment will consist of a blinded syringe of 1cc clear liquid 25mg/ml Promethazine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The treatment will consist of a blinded syringe of 1cc 0.9% Sodium Chloride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Promethazine</intervention_name>
    <description>1cc 25mg/ml Promethazine (study medication)</description>
    <arm_group_label>Promethazine</arm_group_label>
    <other_name>Phenergan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1cc 0.9% Sodium Chloride (placebo)</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>salt water</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant adult female patients of at least 18 years of age consenting to a cesarean&#xD;
             birth&#xD;
&#xD;
          -  Willing to consent to study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Male patients&#xD;
&#xD;
          -  Incarceration&#xD;
&#xD;
          -  Inability to communicate with the investigators&#xD;
&#xD;
          -  Allergies to any medications used in the study&#xD;
&#xD;
          -  Possessing any contraindication to spinal anesthesia (lack of consent, elevated&#xD;
             intracranial pressure, preexisting neurological disease,&#xD;
             thrombocytopenia/coagulopathy, hypovolemia, infection at the site of the procedure)&#xD;
&#xD;
          -  Patients with an already prolonged QTc (&gt;500 ms)&#xD;
&#xD;
          -  Any reason an investigator believes study participation would not be in the best&#xD;
             interest of the potential subject.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant adult female patients of at least 18 years of age consenting to a cesarean birth.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Cates, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara Harris</last_name>
    <phone>352-273-6786</phone>
    <email>SCroft@anest.ufl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy Gunnett</last_name>
    <phone>352-273-8911</phone>
    <email>AGunnett@anest.ufl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UF Health at the University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Gunnett</last_name>
      <phone>352-273-8911</phone>
      <email>AGunnett@anest.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Cates, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Cometa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 15, 2021</study_first_submitted>
  <study_first_submitted_qc>March 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cesarean section</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

